Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Case Report

Amphotericin-B-Induced Chronic Kidney Disease in a Post-COVID-19 Patient with Widespread Rhinocerebral Mucormycosis and Pneumonia: A Case Report

Author(s): Nishant Johri*, Ambika Choudhary, Ujjawal Rawat and Maheshwari Vengat

Volume 19, Issue 4, 2024

Published on: 29 August, 2023

Page: [474 - 477] Pages: 4

DOI: 10.2174/1574886318666230804101539

Price: $65

Abstract

Background: The COVID-19 pandemic has posed a unique challenge to the medical community due to potential co-infections with bacteria and fungi. We report a case of Rhino cerebral mucormycosis infection in a 67-year-old patient after recovery from COVID-19.

Objective: To report a case of Rhino cerebral mucormycosis in a 67-year-old patient with preexisting health conditions after recovering from COVID-19 and to highlight the importance of early detection and treatment of co-infections in patients with pre-existing health conditions.

Case Presentation: The patient had pre-existing health conditions, including uncontrolled diabetes, hypertension, and Chronic obstructive pulmonary disease (COPD), which made him more vulnerable to complications after COVID-19. He was admitted to the hospital after experiencing a dark discharge from his left eye, later confirmed to be due to mucormycosis. Histopathological examination revealed invasive mucormycosis, highlighting the importance of early detection and treatment. However, the patient experienced Acute kidney injury (AKI) after only 5 days of treatment with conventional amphotericin B, underscoring the need for careful monitoring and adjustment of treatment regimens.

Discussion: The case underscores the need for early detection and treatment of co-infections in vulnerable patients. The patient's pre-existing conditions and immunocompromised state made him more susceptible to the infection. The case also highlights the importance of careful monitoring and adjustment of treatment regimens to minimize the risk of adverse effects.

Conclusion: While COVID-19 has presented challenges and uncertainties, it has also provided valuable insights into the interactions between infectious agents and the human body. Continued research and vigilance are necessary to mitigate the impact of co-infections and improve outcomes for patients.

« Previous Next »
Graphical Abstract

[1]
Eucker J, Sezer O, Graf B, Possinger K. Mucormycoses. Mycoses 2001; 44(7-8): 253-60.
[http://dx.doi.org/10.1111/j.1439-0507.2001.00656.x] [PMID: 11714058]
[2]
Thomas DL, Lemon SM, Mandell GL, Bennett JE, Dolin R. Principles and practice of infectious diseases. New York: Churchil Livingstone 2000.
[3]
Laniado-Laborín R, Cabrales-Vargas MN. Amphotericin B: Side effects and toxicity. Rev Iberoam Micol 2009; 26(4): 223-7.
[http://dx.doi.org/10.1016/j.riam.2009.06.003] [PMID: 19836985]
[4]
Bottone EJ, Weitzman I, Hanna BA. Rhizopus rhizopodiformis: Emerging etiological agent of mucormycosis. J Clin Microbiol 1979; 9(4): 530-7.
[http://dx.doi.org/10.1128/jcm.9.4.530-537.1979] [PMID: 457856]
[5]
Ferguson BJ, Mitchell TG, Moon R, Camporesi EM, Farmer J. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Clin Infect Dis 1988; 10(3): 551-9.
[http://dx.doi.org/10.1093/clinids/10.3.551] [PMID: 3393782]
[6]
Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: An update. J Fungi 2020; 6(4): 265.
[http://dx.doi.org/10.3390/jof6040265] [PMID: 33147877]
[7]
Wang H, Xia W, Long G, et al. Isoquercitrin ameliorates cisplatin-induced nephrotoxicity via the inhibition of apoptosis, inflammation, and oxidative stress. Front Pharmacol 2020; 11: 599416.
[http://dx.doi.org/10.3389/fphar.2020.599416] [PMID: 33424608]
[8]
Rocha PN, Kobayashi CD, de Carvalho Almeida L, de Oliveira dos Reis C, Santos BM, Glesby MJ. Incidence, predictors, and impact on hospital mortality of amphotericin B nephrotoxicity defined using newer acute kidney injury diagnostic criteria. Antimicrob Agents Chemother 2015; 59(8): 4759-69.
[http://dx.doi.org/10.1128/AAC.00525-15] [PMID: 26014956]
[9]
Hoang K, Abdo T, Reinersman JM, Lu R, Higuita NIA. A case of invasive pulmonary mucormycosis resulting from short courses of corticosteroids in a well-controlled diabetic patient. Med Mycol Case Rep 2020; 29: 22-4.
[http://dx.doi.org/10.1016/j.mmcr.2020.05.008] [PMID: 32547914]
[10]
Sanchez MR, Ponge-Wilson I, Moy JA, Rosenthal S. Zygomycosis and HIV infection. J Am Acad Dermatol 1994; 30(5): 904-8.
[http://dx.doi.org/10.1016/S0190-9622(94)70110-5] [PMID: 8169272]
[11]
Parfrey NA. Improved diagnosis and prognosis of mucormycosis. A clinicopathologic study of 33 cases. Medicine 1986; 65(2): 113-23.
[http://dx.doi.org/10.1097/00005792-198603000-00004] [PMID: 3951358]
[12]
Arastehfar A, Carvalho A, van de Veerdonk FL, et al. COVID-19 associated pulmonary aspergillosis (CAPA)—from immunology to treatment. J Fungi 2020; 6(2): 91.
[http://dx.doi.org/10.3390/jof6020091] [PMID: 32599813]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy